Eric was the founding CEO of TearLab Corporation, a publicly traded, in-vitro diagnostics company (NASDAQ:TEAR) that has successfully commercialized the only CLIA-waived, point-of-care, testing platform capable of measuring disease markers in tears for the rapid and quantitative diagnosis of eye diseases. Mr. Donsky was also the founding CEO of Applied CarboChemicals, Inc. (“ACC”), since renamed BioAmber, which is a leading bio-based chemical and materials company. BioAmber (NYSE:BIOA) has developed the 1st process capable of economically manufacturing succinic acid through fermentation at large scale using a novel genetically-engineered bacterial strain original licensed from the U.S. Department of Energy. Succinic acid serves as a chemical intermediate for the synthesis of a vast range of derivative chemistries that function as detergent additives, monomers, polymers, coatings, solvents, among many other applications. The Company has several manufacturing plants under construction on 3 continents and has $4B of contracted revenues. BioAmber has formed strategic partnerships with DuPont, Cargill, Lanxess, Mitsubishi and Mitsui.